X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
index medicus (12) 12
female (11) 11
papillomavirus infections - prevention & control (10) 10
adult (9) 9
cervical cancer (9) 9
cervical intraepithelial neoplasia - prevention & control (9) 9
adolescent (8) 8
double-blind method (8) 8
human papillomavirus (8) 8
human papillomavirus 16 - immunology (8) 8
human papillomavirus 18 - immunology (8) 8
papillomavirus infections (8) 8
papillomavirus vaccines - administration & dosage (8) 8
vaccines (8) 8
young-women (8) 8
cervical intraepithelial neoplasia - virology (7) 7
particle vaccine (7) 7
adjuvants, immunologic - administration & dosage (6) 6
analysis (6) 6
clinical trials (6) 6
young adult (6) 6
health aspects (5) 5
of-study analysis (5) 5
papillomavirus vaccines - immunology (5) 5
prevention (5) 5
treatment outcome (5) 5
uterine cervical neoplasms - prevention & control (5) 5
uterine cervical neoplasms - virology (5) 5
vaccination (5) 5
broad-spectrum (4) 4
cancer (4) 4
hematology, oncology and palliative medicine (4) 4
invasive cervical-cancer (4) 4
lipid a - analogs & derivatives (4) 4
oncology (4) 4
papillomavirus vaccines - therapeutic use (4) 4
research (4) 4
womens health (4) 4
abridged index medicus (3) 3
aluminum hydroxide - administration & dosage (3) 3
antibodies, viral - blood (3) 3
costa rica (3) 3
follow-up (3) 3
follow-up studies (3) 3
human papillomavirus 16 - genetics (3) 3
human papillomavirus 18 - genetics (3) 3
infection (3) 3
infectious diseases (3) 3
lipid a - administration & dosage (3) 3
middle aged (3) 3
papillomavirus infections - virology (3) 3
papillomaviruses (3) 3
time factors (3) 3
age (2) 2
age factors (2) 2
aged 16-26 years (2) 2
asia (2) 2
australia (2) 2
cervical intraepithelial neoplasia - diagnosis (2) 2
cervical intraepithelial neoplasia - immunology (2) 2
cervical intraepithelial neoplasia - pathology (2) 2
child (2) 2
clinical-trial (2) 2
controlled-trial (2) 2
cross infection (2) 2
cross reactions (2) 2
dna (2) 2
dna, viral - analysis (2) 2
double-blind (2) 2
epitopes (2) 2
europe (2) 2
hpv types (2) 2
hpv vaccination (2) 2
hpv vaccine (2) 2
hpv-16/18 as04-adjuvanted vaccine (2) 2
human medicine (2) 2
human-papillomavirus infection (2) 2
human-papillomavirus type-16 (2) 2
immunization (2) 2
immunogenicity (2) 2
immunology (2) 2
infections (2) 2
internal medicine (2) 2
intraepithelial neoplasia (2) 2
major capsid protein (2) 2
medical colleges (2) 2
medicine, general & internal (2) 2
neoplasm grading (2) 2
north america (2) 2
nosocomial infections (2) 2
oncology, experimental (2) 2
papillomavirus infections - diagnosis (2) 2
papillomavirus infections - immunology (2) 2
patricia trial (2) 2
pooled analysis (2) 2
public health (2) 2
quadrivalent vaccine (2) 2
south america (2) 2
uterine cervical neoplasms - diagnosis (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 89 - 99
Summary Background Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate endpoint used in licensure trials of human papillomavirus... 
Hematology, Oncology and Palliative Medicine | COUNTRIES | ONCOLOGY | PARTICLE VACCINE | ADENOCARCINOMA | HPV VACCINATION | ADOLESCENT WOMEN | FOLLOW-UP | YOUNG-WOMEN | CANCER | CARCINOMA | HUMAN-PAPILLOMAVIRUS INFECTION | South America | Cervical Intraepithelial Neoplasia - pathology | Human papillomavirus 18 - immunology | Adenocarcinoma - pathology | Adjuvants, Immunologic - administration & dosage | Age Factors | Humans | Lipid A - analogs & derivatives | DNA, Viral - analysis | Uterine Cervical Neoplasms - pathology | Aluminum Hydroxide - administration & dosage | Human papillomavirus 16 - immunology | North America | Papillomavirus Infections - diagnosis | Young Adult | Neoplasm Grading | Time Factors | Adult | Female | Papillomavirus Infections - virology | Human papillomavirus 18 - genetics | Papillomavirus Vaccines - administration & dosage | Lipid A - administration & dosage | Uterine Cervical Neoplasms - diagnosis | Double-Blind Method | Europe | Uterine Cervical Neoplasms - prevention & control | Cervical Intraepithelial Neoplasia - diagnosis | Treatment Outcome | Adenocarcinoma - virology | Cervical Intraepithelial Neoplasia - virology | Adenocarcinoma - diagnosis | Adenocarcinoma - prevention & control | Asia | Papillomavirus Infections - prevention & control | Adolescent | Cervical Intraepithelial Neoplasia - prevention & control | Uterine Cervical Neoplasms - virology | Australia | Human papillomavirus 16 - genetics | Medical colleges | Care and treatment | Cervix dysplasia | Vaccination | Oncology, Experimental | Clinical trials | Vaccines | Research | Prevention | Sexually transmitted diseases | Analysis | Cross infection | Adults | Nosocomial infections | Children | Papillomavirus infections | Health aspects | Cervical cancer | Public health | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 100 - 110
Summary Background We evaluated the efficacy of the human papillomavirus HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types in the... 
Hematology, Oncology and Palliative Medicine | UNITED-STATES | AGED 16-26 YEARS | ONCOLOGY | PARTICLE VACCINE | NEOPLASIA | MAJOR CAPSID PROTEIN | YOUNG-WOMEN | CANCER | HUMAN-PAPILLOMAVIRUS INFECTION | LESIONS | EPITOPES | South America | Cervical Intraepithelial Neoplasia - pathology | Human papillomavirus 18 - immunology | Adjuvants, Immunologic - administration & dosage | Humans | Lipid A - analogs & derivatives | DNA, Viral - analysis | Uterine Cervical Neoplasms - pathology | Aluminum Hydroxide - administration & dosage | Human papillomavirus 16 - immunology | North America | Papillomavirus Infections - diagnosis | Young Adult | Neoplasm Grading | Precancerous Conditions - diagnosis | Precancerous Conditions - virology | Time Factors | Adult | Female | Papillomavirus Infections - virology | Precancerous Conditions - pathology | Human papillomavirus 18 - genetics | Papillomavirus Vaccines - administration & dosage | Lipid A - administration & dosage | Uterine Cervical Neoplasms - diagnosis | Double-Blind Method | Europe | Uterine Cervical Neoplasms - prevention & control | Cervical Intraepithelial Neoplasia - diagnosis | Treatment Outcome | Cervical Intraepithelial Neoplasia - virology | Cross Reactions | Antigens, Viral - immunology | Asia | Papillomavirus Infections - prevention & control | Adolescent | Cervical Intraepithelial Neoplasia - prevention & control | Uterine Cervical Neoplasms - virology | Precancerous Conditions - prevention & control | Australia | Human papillomavirus 16 - genetics | Prevention | Medical colleges | Analysis | Oncology, Experimental | Clinical trials | Cross infection | Vaccines | Nosocomial infections | Research | Papillomavirus infections | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9580, pp. 2161 - 2170
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 10, pp. 1154 - 1168
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9961, pp. 2213 - 2227
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 775 - 786
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 07/2017, Volume 109, Issue 7, p. djw300
Journal Article
Journal Article